NRX PHARMACEUTICALS INC
NRX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that develops therapeutics for the treatment of central nervous system disorders and both the treatment and prevention of pulmonary diseases through its wholly owned operating subsidiary, NeuroRx, Inc. Its NRX-100 and NRX-101 are N-methyl-D-aspartate (NMDA) -targeted medicines designed to address both depression and suicidal ideation. NRX-101 is a fixed-dose combination of D-cycloserine and lurasidone for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB). Its ZYESAMI (aviptadil) is an investigational drug for COVID-19-related respiratory failure. The Company has completed a Phase IIb/III clinical study in patients with acute respiratory failure in COVID-19.
Buy US stocks in Australia starting with NRXP. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in NRXP
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.